No abstract

No abstract

The serious drawbacks of the conventional treatment of pancreatic ductal adenocarcinoma (PDAC) such as nonspecific toxicity and high resistance to chemo and radiation therapy, have prompted the development and application of countless small interfering RNA (siRNA)‐based therapeutics. Recent advances in drug delivery systems hold great promise for improving siRNA‐based therapeutics and developing a new class of drugs, known as nano‐siRNA drugs. However, many fundamental questions, regarding toxicity, immunostimulation, and poor knowledge of nano‐bio interactions, need to be addressed before clinical translation. In this review, we provide recent achievements in the design and development of various nonviral delivery vehicles for pancreatic cancer therapy. More importantly, codelivery of conventional anticancer drugs with siRNA as a new revolutionary pancreatic cancer combinational therapy is completely discussed.

Glioblastoma multiforme (GBM) is the most common and lethal primary malignant brain tumor in adults. In spite of substantial progress in the understanding of gliomas biology, there has been only a slight change in the treatment of these types of tumors in the past few years. Moreover, chemotherapeutic strategies for GBM are accompanied by a lack of selectivity, serious side effects, and drug resistance. Recently, the emergence of cold atmospheric plasma (CAP), a quasi-neutral highly reactive (partially) ionized gas at close to room temperature, technology has heralded a new exciting era in cancer therapy. CAP generates a unique, rich environment of reactive oxygen and nitrogen species, photons, charged ions, and an electric field, which makes it a promising robust tool for the treatment of different types of cancers. In this review, we present recent progress of CAP in the treatment of GBM. Most importantly, the combination of CAP-based therapeutic systems and other cancer therapies including chemotherapy and nanotherapy that offer great potential for GBM therapy is covered.

Objective:Medication Therapy Management service (MTMs) has been introduced to improve cooperation among pharmacists and other healthcare professionals in the management of chronic diseases, drug therapy, and patients on polypharmacy. One part of MTMs is detection and resolution of possible drug-related problems (DRPs). Nowadays, numerous DRPs classification systems are available, but due to some defects none of them are currently accepted and implemented universally. The purpose of this study is to design and validate a comprehensive system for classification and documentation of possible DRPs for the Iranian patients.Methods:In this methodological study, four classification systems were studied, and their differences were reviewed, compared. Ultimately, a comprehensive documentation system was developed and tested for validity using experts' opinions.Findings:A comprehensive list of 53 DRPs under eight categories was developed and examined for validity. After collecting the data and validity assessment, questions with content validity ratio of <0.4 and content validity index of <70% were excluded and modified. Finally, with the exclusion and modification of eight DRPs, a modified DRPs list was created.Conclusion:According to the universality and validity assessment and based on consensus of 20 experts, this DRPs list can be used to regulate the standard operation procedure of outpatient clinics in Iran, and could act toward standardization of this service.